Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wenshen Bugu Decoction is a traditional Chinese medicine (TCM) herbal formula composed of multiple medicinal herbs. It is primarily used to decrease bone loss and reduce the risk of fracture, especially in postmenopausal women with breast cancer who are experiencing aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). The decoction contains a combination of herbs including Astragalus (Huangqi), Codonopsis (Dangshen), Atractylodes (Baizhu), Poria cocos (Fuling), Adenophora tetraphylla (Nanshashen), Epimedium (Xianlingpi), Morinda officinalis (Bajitian), Cistanche deserticola (Roucongrong), Curcuma zedoaria (Ezhu), Salvia chinensis, Fructus Psoraleae, Rhizoma Drynariae, Achyranthes bidentata, Himalayan Teasel Root, Anemarrhena asphodeloides, and Cortex Phellodendri. The mechanism of action is not fully elucidated but is believed to involve multi-target modulation such as nourishing kidney function and strengthening bones according to TCM theory. Clinical studies suggest it may help mitigate bone loss induced by aromatase inhibitors in breast cancer patients[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Wenshen Bugu Decoction.